Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408832 | 0.83 | TSHR (0.68) | RAB9ATSHRSMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL4160236 | 0.79 | RAB9A (0.48) | RAB9AKMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL3401213 | 0.77 | TSHR (0.48) | RAB9ATSHRSMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL26653746 | 0.76 | HSD17B10 (0.54) | RAB9ATSHRSMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL16230884 | 0.76 | TSHR (0.46) | RAB9AKMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL28514263 | 0.76 | NPC1 (0.49) | RAB9ASMN1; SMN2NPC1L3MBTL1MAPK1 | |
| SCHEMBL28512799 | 0.75 | RAB9A (0.48) | RAB9AKMT2ASMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL4166156 | 0.73 | RAB9A (0.43) | RAB9AKMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL18172092 | 0.73 | CA12 (0.41) | RAB9AKMT2ATSHRSMN1; SMN2DEGS1 | |
| SCHEMBL28510730 | 0.71 | MAPK1 (0.51) | RAB9ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | RAB9A 2815/4885KMT2A 3374/4885TSHR 3652/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | RAB9A 2629/4885KMT2A 3173/4885TSHR 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.